CML-046 Dose Modification Dynamics of Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia From the PACE and OPTIC Trials

Objective: In the PACE trial (NCT01207440), patients with resistant/intolerant chronic-phase chronic myeloid leukemia (CP-CML) demonstrated lasting responses to ponatinib 45 mg once daily (QD). The OPTIC trial (NCT02467270) prospectively evaluated a response-based dose-reduction strategy to optimize...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2022-10, Vol.22, p.S284-S285
Hauptverfasser:	Apperley, Jane, Kantarjian, Hagop, Deininger, Michael, Abruzzese, Elisabetta, Cortes, Jorge, Chuah, Charles, DeAngelo, Daniel J., DiPersio, John, Hochhaus, Andreas, Lipton, Jeffrey H., Nicolini, Frank, Pinilla-Ibarz, Javier, Rea, Delphine, Rosti, Gianantonio, Rousselot, Philippe, Mauro, Michael, Shah, Neil, Talpaz, Moshe, Vorog, Alexander, Ren, Xiaowei, Jabbour, Elias
Format:	Artikel
Sprache:	eng
Schlagworte:	Life Sciences
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!